MedTrace Logo

WearAble Technology for Collecting Health Data in People Who Are the Transfused (WATCH Transfused) - A UK Exploratory Study to Improve Quality of Life and the Efficacy of Transfusion Supportive Care in People With Blood Cancers Undergoing Treatment

NCT07511829 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 80

Last updated 2026-04-06

No results posted yet for this study

Summary

Cancer treatments such as chemotherapy often affect healthy cells as well as the cancer cells and this can lead to side-effects such as low blood counts - anaemia. This can cause severe fatigue, shortness of breath and brain fog and may need regular blood transfusions. Their quality of life (QoL) is often very poor during treatment because of these side effects, and it is hard to deal with.

Doctors use blood tests to decide whether a patient is well enough for treatment and when to start treatment. However, blood tests do not tell us how a person feels, and it is not the same in everyone. We need a better way for doctors to monitor patients' QoL and these symptoms so that they are physically and emotionally able to continue their treatment. It is hard for doctors to accurately assess this through speaking to their patients and doctors do not record or discuss these effects of treatment very well with patients.

The aim of this study is to better understand how people feel during their treatment and how we can best use blood transfusions to maintain QoL.

80 adult patients who are starting blood cancer treatments will be asked to answer questionnaires about how they are feeling and their symptoms during their treatment. Participants will be asked to wear a smartwatch to measure their physical activity levels. Activity data collected will then be compared with their reported QoL and blood counts to help us understand when patients can tolerate difficult treatments the best and how blood transfusions affect this.

Patients, their family and carers will be invited to take part in an interview to understand their views on how we can improve their care, QoL and access to transfusions.

A better understanding of the impact of low blood counts on QoL can help us use blood transfusions to benefit patients' lives. This work will better match transfusions to individual peoples' needs and therefore 'personalise' blood transfusion care.

Conditions

  • MDS (Myelodysplastic Syndrome)
  • AML (Acute Myeloid Leukemia)

Interventions

DEVICE

Axvitiy Ax3 accelorometer

Participants will wear the accelometer for 2 months

Sponsors & Collaborators

  • University of Oxford

    lead OTHER

Principal Investigators

  • Matthew H Poynton, MBBS · University of Oxford

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-02-17
Primary Completion
2027-04-01
Completion
2027-09-01

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07511829 on ClinicalTrials.gov